{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T10:11:27Z","timestamp":1792145487318,"version":"4.4.0"},"reference-count":15,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,3,11]],"date-time":"2025-03-11T00:00:00Z","timestamp":1741651200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","cysticfibrosisjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Cystic Fibrosis"],"published-print":{"date-parts":[[2025,5]]},"DOI":"10.1016\/j.jcf.2025.03.008","type":"journal-article","created":{"date-parts":[[2025,3,14]],"date-time":"2025-03-14T12:19:22Z","timestamp":1741954762000},"page":"526-533","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"title":["Real-world pharmacokinetics of elexacaftor-tezacaftor-ivacaftor in children with cystic fibrosis: a prospective observational study"],"prefix":"10.1016","volume":"24","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9905-7805","authenticated-orcid":false,"given":"Steffie E.M.","family":"Vonk","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suzanne W.J.","family":"Terheggen-Lagro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric G.","family":"Haarman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8995-3817","authenticated-orcid":false,"given":"S.","family":"Hashimoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anke H.","family":"Maitland-van der Zee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ron A.A.","family":"Math\u00f4t","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2275-1713","authenticated-orcid":false,"given":"E. Marleen","family":"Kemper","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.jcf.2025.03.008_bib0001","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1016\/j.jcf.2023.03.002","article-title":"Real-world safety and effectiveness of elexacaftor\/tezacaftor\/ivacaftor in people with cystic fibrosis: interim results of a long-term registry-based study","volume":"22","author":"Bower","year":"2023","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.jcf.2025.03.008_bib0002","series-title":"Nederlandse CF Registratie Jaarrapport 2022","year":"2023"},{"key":"10.1016\/j.jcf.2025.03.008_bib0003","series-title":"Summary of Product Characteristics - KAFTRIO","year":"2020"},{"key":"10.1016\/j.jcf.2025.03.008_bib0004","unstructured":"FDA. Multi-discipline review trikafta (Elexacaftor\/Tezacaftor\/Ivacaftor). 2019 (Last accessed on: 17\u20138-2020)."},{"issue":"12","key":"10.1016\/j.jcf.2025.03.008_bib0005","doi-asserted-by":"crossref","first-page":"1522","DOI":"10.1164\/rccm.202102-0509OC","article-title":"A phase 3 open-label study of Elexacaftor\/Tezacaftor\/Ivacaftor in children 6 through 11 years of age with cystic fibrosis and at least one F508del Allele","volume":"203","author":"Zemanick","year":"2021","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.jcf.2025.03.008_bib0006","article-title":"A quantitative method for the analysis of ivacaftor, hydroxymethyl ivacaftor, ivacaftor carboxylate, lumacaftor, and tezacaftor in plasma and sputum using LC-MS\/MS and its clinical applicability","author":"Vonk","year":"2020","journal-title":"Ther Drug Monit"},{"key":"10.1016\/j.jcf.2025.03.008_bib0007","doi-asserted-by":"crossref","DOI":"10.1097\/FTD.0000000000001231","article-title":"Dried blood spot method development and clinical validation for the analysis of elexacaftor, Elexacaftor-M23, Tezacaftor, Tezacaftor-M1, ivacaftor, ivacaftor carboxylate, and hydroxymethyl ivacaftor using LC-MS\/MS","author":"Vonk","year":"2024","journal-title":"Ther Drug Monit"},{"issue":"2","key":"10.1016\/j.jcf.2025.03.008_bib0008","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1007\/s41030-020-00124-7","article-title":"Physiologically based pharmacokinetic modeling of CFTR modulation in people with cystic fibrosis transitioning from mono or dual regimens to triple-combination Elexacaftor\/Tezacaftor\/Ivacaftor","volume":"6","author":"Tsai","year":"2020","journal-title":"Pulm Ther"},{"issue":"7","key":"10.1016\/j.jcf.2025.03.008_bib0009","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1007\/s00228-008-0493-7","article-title":"How many subjects are necessary for population pharmacokinetic experiments? Confidence interval approach","volume":"64","author":"Ogungbenro","year":"2008","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1016\/j.jcf.2025.03.008_bib0010","unstructured":"FDA. Clinical pharmacology and biopharmaceutics review symdeko (Tezacaftor\/ivacaftor). 201,728-06-2017."},{"key":"10.1016\/j.jcf.2025.03.008_bib0011","unstructured":"FDA. Clinical pharmacology review kalydeco (Ivacaftor). 201,227-01-2012."},{"key":"10.1016\/j.jcf.2025.03.008_bib0012","unstructured":"Rowland M. TTN. Clinical pharmacokinetics and pharmacodynamics. 4th Edition ed: Lippincott Williams & Wilkins, a Wolters Kluwer business; 2011."},{"key":"10.1016\/j.jcf.2025.03.008_bib0013","doi-asserted-by":"crossref","DOI":"10.1007\/s40262-023-01342-3","article-title":"Lumacaftor\/Ivacaftor population pharmacokinetics in pediatric patients with Cystic fibrosis: a first step toward personalized therapy","author":"Bouazza","year":"2024","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.jcf.2025.03.008_bib0014","doi-asserted-by":"crossref","DOI":"10.1016\/j.pupt.2024.102301","article-title":"Pharmacokinetic variability of CFTR modulators from standard and alternative regimens","volume":"86","author":"Rose","year":"2024","journal-title":"Pulm Pharmacol Ther"},{"issue":"4","key":"10.1016\/j.jcf.2025.03.008_bib0015","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1002\/phar.2786","article-title":"Safety of elexacaftor\/tezacaftor\/ivacaftor dose reduction: mechanistic exploration through physiologically based pharmacokinetic modeling and a clinical case series","volume":"43","author":"Hong","year":"2023","journal-title":"Pharmacotherapy"}],"container-title":["Journal of Cystic Fibrosis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1569199325000761?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1569199325000761?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,6,3]],"date-time":"2025-06-03T20:29:15Z","timestamp":1748982555000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1569199325000761"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5]]},"references-count":15,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,5]]}},"alternative-id":["S1569199325000761"],"URL":"https:\/\/doi.org\/10.1016\/j.jcf.2025.03.008","relation":{},"ISSN":["1569-1993"],"issn-type":[{"value":"1569-1993","type":"print"}],"subject":[],"published":{"date-parts":[[2025,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Real-world pharmacokinetics of elexacaftor-tezacaftor-ivacaftor in children with cystic fibrosis: a prospective observational study","name":"articletitle","label":"Article Title"},{"value":"Journal of Cystic Fibrosis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jcf.2025.03.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier B.V. on behalf of European Cystic Fibrosis Society.","name":"copyright","label":"Copyright"}]}}